MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)

– Primary endpoint achieved statistically significant improvement in MDD symptoms –


– Confirmation of activity of lysergide in brain health disorders with direct relevance to... | April 14, 2023

Related Keywords

Switzerland ,Canada ,Canadian ,Robert Barrow ,Matthias Liechti ,Felix Mueller ,Medicine Mindmed Inc ,University Hospital Basel ,Nasdaq ,Company Or Mindmed ,Liechti Lab ,University Hospital Of Psychiatry ,Mind Medicine ,University Hospital ,Depressive Symptomatology ,Chief Executive Officer ,Initiated Clinical ,Beck Depression Index ,Mind Medicine Mindmed Stock Exchange ,News ,Information ,Press Release ,Primary ,Ndpoint ,Chieved ,Statistically ,Significant ,Improvement ,N ,Odd ,Symptoms ,Confirmation ,F ,Activity ,Ysergide ,Rain ,Health ,Disorders ,Ith ,Direct ,Elevance Mnmd Ca60255c8850 ,